Metabolic Syndrome Increases Risk for Pulmonary Embolism After Hip and Knee Arthroplasty

Overview

Journal Croat Med J

Specialty General Medicine

Date 2013 Aug 30

PMID 23986276

Citations 4

Authors

Boris Mraovic

Brian R Hipszer

Richard H Epstein

Javad Parvizi

Edward C Pequignot

Inna Chervoneva

Jeffery I Joseph

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate whether patients with metabolic syndrome (MetS) undergoing total hip or knee replacement have an increased risk for pulmonary embolism (PE).

Methods: We studied patients undergoing total hip or total knee replacement from January 2001 to April 2006. The diagnosis of PE was based on a positive finding with a chest CT or a lung scan. Components of MetS were defined as 1) BMI≥30 kg/m(2) , 2) non-fasting preadmission glucose ≥11.1 mmol/L or diagnosis of diabetes, 3) hypertension, and 4) dyslipidemia. MetS was diagnosed if at least three of these components were present.

Results: Of 7282 patients, 107 (1.47%) were diagnosed with PE. The incidence of PE in patients with 0, 1, 2, 3, and 4 MetS components was respectively 0.85% (16/1888; 95% confidence interval [CI] 0.5%-1.4%), 1.24% (31/2500; 95% CI 0.9%-1.8%), 1.76% (34/1936; 95% CI 1.2%-2.5%), 2.64% (21/796; 95% CI 1.7%-4.1%), and 3.09% (5/162; 95% CI 1.1%-7.4%). The independent risk factors for PE were age ≥70, knee as opposite to hip replacement, bilateral knee surgery, congestive heart failure, and MetS or the number of MetS components. The odds of PE independently increased 1.6 times (95% CI 1.01-2.56; P=0.043) for patients with MetS and 1.23 times (95% CI 1.02-1.48; P=0.028) per each additional MetS component.

Conclusion: Patients with MetS are at increased risk for PE after total joint arthroplasty. The increasing number of MetS components significantly increased the incidence of PE.

Citing Articles

COVID-19 infection-associated coagulopathy: Pathophysiology and clinical implications.

Abutaleb A, Nathan S Interv Neuroradiol. 2021; 27(1_suppl):6-12.

PMID: 34747644 PMC: 8579353. DOI: 10.1177/15910199211035894.

Association between metabolic syndrome and venous thromboembolism after total joint arthroplasty: a meta-analysis of cohort studies.

Yang Y, Li Z, Liang H, Tian J J Orthop Surg Res. 2020; 15(1):570.

PMID: 33256765 PMC: 7706034. DOI: 10.1186/s13018-020-02097-4.

Metabolic syndrome increases risk for perioperative outcomes following posterior lumbar interbody fusion.

He X, Fei Q, Sun T Medicine (Baltimore). 2020; 99(38):e21786.

PMID: 32957307 PMC: 7505287. DOI: 10.1097/MD.0000000000021786.

Patients with metabolic syndrome have a greater rate of complications after arthroplasty: A systematic review and meta-analysis.

Guofeng C, Chen Y, Rong W, Ruiyu L, Kunzheng W Bone Joint Res. 2020; 9(3):120-129.

PMID: 32435464 PMC: 7229294. DOI: 10.1302/2046-3758.93.BJR-2019-0138.R1.

References

Cheung B, Ong K, Man Y, Wong L, Lau C, Lam K . Prevalence of the metabolic syndrome in the United States National Health and Nutrition Examination Survey 1999-2002 according to different defining criteria. J Clin Hypertens (Greenwich). 2006; 8(8):562-70. PMC: 8109527. DOI: 10.1111/j.1524-6175.2006.05414.x. View

Dentali F, Romualdi E, Ageno W . The metabolic syndrome and the risk of thrombosis. Haematologica. 2007; 92(3):297-9. DOI: 10.3324/haematol.11243. View

Huo M, Salvati E, Sharrock N, Brien W, Sculco T, Pellicci P . Intraoperative heparin thromboembolic prophylaxis in primary total hip arthroplasty. A prospective, randomized, controlled, clinical trial. Clin Orthop Relat Res. 1992; (274):35-46. View

Ford E . Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005; 28(11):2745-9. DOI: 10.2337/diacare.28.11.2745. View

Ambrosetti M, Ageno W, Salerno M, Pedretti R, Salerno-Uriarte J . Metabolic syndrome as a risk factor for deep vein thrombosis after acute cardiac conditions. Thromb Res. 2007; 120(6):815-8. DOI: 10.1016/j.thromres.2007.02.005. View

Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R . The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost. 2006; 4(9):1914-8. DOI: 10.1111/j.1538-7836.2006.02132.x. View

Mraovic B, Hipszer B, Epstein R, Pequignot E, Parvizi J, Joseph J . Preadmission hyperglycemia is an independent risk factor for in-hospital symptomatic pulmonary embolism after major orthopedic surgery. J Arthroplasty. 2008; 25(1):64-70. DOI: 10.1016/j.arth.2008.10.002. View

White R, Romano P, Zhou H, Rodrigo J, Bargar W . Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158(14):1525-31. DOI: 10.1001/archinte.158.14.1525. View

Bjornara B, Gudmundsen T, Dahl O . Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br. 2006; 88(3):386-91. DOI: 10.1302/0301-620X.88B3.17207. View

10.

Parvizi J, Smith E, Pulido L, Mamelak J, Morrison W, Purtill J . The rise in the incidence of pulmonary embolus after joint arthroplasty: is modern imaging to blame?. Clin Orthop Relat Res. 2007; 463:107-13. DOI: 10.1097/BLO.0b013e318145af41. View

11.

Mantilla C, Horlocker T, Schroeder D, Berry D, Brown D . Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology. 2003; 99(3):552-60; discussion 5A. DOI: 10.1097/00000542-200309000-00009. View

12.

Warwick D, Friedman R, Agnelli G, Gil-Garay E, Johnson K, Fitzgerald G . Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007; 89(6):799-807. DOI: 10.1302/0301-620X.89B6.18844. View

13.

Zhan C, Kaczmarek R, Loyo-Berrios N, Sangl J, Bright R . Incidence and short-term outcomes of primary and revision hip replacement in the United States. J Bone Joint Surg Am. 2007; 89(3):526-33. DOI: 10.2106/JBJS.F.00952. View

14.

Ray J . Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med. 2003; 9(5):378-84. DOI: 10.1097/00063198-200309000-00007. View

15.

Brietzke S . Controversy in diagnosis and management of the metabolic syndrome. Med Clin North Am. 2007; 91(6):1041-61, vii-viii. DOI: 10.1016/j.mcna.2007.06.005. View

16.

Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovich T . Venous thromboembolism--a manifestation of the metabolic syndrome. Haematologica. 2007; 92(3):374-80. DOI: 10.3324/haematol.10828. View

17.

Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17):2735-52. DOI: 10.1161/CIRCULATIONAHA.105.169404. View

18.

Lie S, Engesaeter L, Havelin L, Furnes O, Vollset S . Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand. 2002; 73(4):392-9. DOI: 10.1080/00016470216312 . View

19.

Alexander C, Landsman P, Teutsch S, Haffner S . NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003; 52(5):1210-4. DOI: 10.2337/diabetes.52.5.1210. View